• Philip Morris International (NYSE:PM) is increasing its focus on smoke free products, which now account for over 40% of its revenue mix.
• The company is pursuing pending FDA approvals for new smoke free offerings alongside planned US product launches.
• These moves signal a shift away from traditional tobacco products and a change in how Philip Morris International positions its core business.

For investors watching NYSE:PM, the headline is that a large share of the company’s revenue now comes from smoke free products, with further FDA related milestones still ahead. The stock trades at $181.83, with a 1 year return of 28.4% and a 5 year return of 168.9%, which frames how the market has treated the company during its ongoing business transition.

As Philip Morris International pushes deeper into smoke free categories and prepares for additional US launches, investors may focus less on quarterly fluctuations and more on how this product mix evolves. The key questions are how quickly smoke free volumes grow as a share of sales and how regulatory outcomes, including FDA decisions, influence the company’s long term business profile.

Stay updated on the most important news stories for Philip Morris International by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Philip Morris International.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$181.83 against a consensus target of US$186.22, the price sits roughly 2% below where analysts are grouped.
• ✅ Simply Wall St Valuation: The shares are described as trading about 16.4% below an estimated fair value, which screens as undervalued in this framework.
• ✅ Recent Momentum: A 30 day return of 11.8% suggests investors have recently been rewarding the shares as the smoke free transition story builds.

Check out Simply Wall St's in depth valuation analysis for Philip Morris International.

Key Considerations

• 📊 The shift toward smoke free products and US expansion plans tie the investment case more closely to execution on new categories and regulatory outcomes.
• 📊 You may want to watch the share of revenue from smoke free products, the US$181.83 price versus both the US$186.22 target and any updated fair value work, as well as any FDA milestones.
• ⚠️ The company carries a high level of debt, so funding growth in smoke free products while managing that obligation is an important risk to track.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Philip Morris International analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.